Skip to content
Yondelis(trabectedin)
Yondelis (trabectedin) is a small molecule pharmaceutical. Trabectedin was first approved as Yondelis on 2007-09-17. It is used to treat leiomyosarcoma and liposarcoma in the USA. It has been approved in Europe to treat ovarian neoplasms and sarcoma. It is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Yondelis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trabectedin
Tradename
Company
Number
Date
Products
YONDELISJohnson & JohnsonN-207953 RX2015-10-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
yondelisNew Drug Application2020-09-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
leiomyosarcomaD007890
liposarcomaD008080
Agency Specific
FDA
EMA
Expiration
Code
TRABECTEDIN, YONDELIS, JANSSEN PRODS
2023-04-23PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Trabectedin, Yondelis, Janssen Prods
88955572028-01-07DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01C: Plant alkaloids and other natural products, antineoplastic drugs
L01CX: Other plant alkaloids and natural products in atc
L01CX01: Trabectedin
HCPCS
Code
Description
J9352
Injection, trabectedin, 0.1 mg
Clinical
Clinical Trials
90 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C561451314
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD0125097196735
LeiomyosarcomaD00789049414
LiposarcomaD0080803528
Fallopian tube neoplasmsD005185112
Synovial sarcomaD013584112
Peritoneal neoplasmsD01053411
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80538
Myxoid liposarcomaD018208144
Ewing sarcomaD012512EFO_00001731113
Ovarian epithelial carcinomaD000077216112
Malignant mesotheliomaD00008600222
Neoplasm metastasisD009362EFO_0009708212
Breast neoplasmsD001943EFO_0003869C5022
Endometrial neoplasmsD016889EFO_000423022
Neoplasms by siteD00937122
RhabdomyosarcomaD012208112
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatic insufficiencyD04855011
Neoplasms by histologic typeD00937011
Connective and soft tissue neoplasmsD01820411
B-cell chronic lymphocytic leukemiaD015451C91.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Desmoplastic small round cell tumorD05840511
HemangioendotheliomaD00639011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRABECTEDIN
INNtrabectedin
Description
Trabectedin is a tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. It has a role as an antineoplastic agent, a marine metabolite, an anti-inflammatory agent, an angiogenesis modulating agent and an alkylating agent. It is an organic heteropolycyclic compound, an azaspiro compound, an oxaspiro compound, a bridged compound, a lactone, a polyphenol, an acetate ester, a hemiaminal, an organic sulfide, a tertiary amino compound and an isoquinoline alkaloid.
Classification
Small molecule
Drug classecteinascidin derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4
Identifiers
PDB
CAS-ID114899-77-3
RxCUI1716278
ChEMBL IDCHEMBL450449
ChEBI ID84050
PubChem CID108150
DrugBankDB05109
UNII IDID0YZQ2TCP (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,301 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
362 adverse events reported
View more details